A modified chitosan-based inflammation-regulating nanoplatform as a noninvasive carrier for macromolecular ophthalmic drug delivery toward synergistic AMD treatment.
Аннотация
Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss in the elderly worldwide. Current standard treatment relies on repeated intravitreal injection of anti-vascular endothelial growth factor A (anti-VEGFA), which is associated with invasiveness, poor patient compliance, and variable therapeutic responses. To address this, we developed an ocular-penetrating carrier for topical anti-VEGFA delivery by conjugating eicosapentaenoic acid (EPA) to chitosan (CS), yielding EPA-functionalized chitosan (CS-EPA). Interestingly, CS-EPA retains the antioxidant and anti-inflammatory activities of EPA while enhancing ocular penetration by promoting E-cad redistribution and transient tight-junction modulation. It self-assembles with therapeutic proteins through electrostatic interactions, forming stable nanocomplexes, which can efficiently reach the posterior segment of mice after non-invasive eye drop administration. More importantly, in a laser-induced choroidal neovascularization (CNV) mouse model, CS-EPA/anti-VEGFA eye drops inhibited neovascularization as effectively as intravitreal anti-VEGFA injection. Beyond VEGFA neutralization, CS-EPA directly suppressed the nuclear factor-κB (NF-κB) pathway, reduced pro-inflammatory cytokine production, and alleviated oxidative stress, thereby disrupting the inflammation-angiogenesis cycle driving AMD progression. Therefore, the dual-action CS-EPA, with enhanced ocular penetration and intrinsic anti-inflammatory activity, provides a noninvasive, patient-compliant alternative for AMD treatment and holds promise for treating other posterior segment diseases.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.